BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang YJ, Chen JW, He XS, Zhang HZ, Ling YH, Wen JH, Deng WH, Li P, Yun JP, Xie D, Cai MY. SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas. EBioMedicine 2018;28:62-9. [PMID: 29396302 DOI: 10.1016/j.ebiom.2018.01.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Mezale D, Strumfa I, Vanags A, Kalva A, Balodis D, Strumfs B, Fridrihsone I, Abolins A, Gardovskis J. Diagnostic Algorithm of Hepatocellular Carcinoma: Classics and Innovations in Radiology and Pathology. In: Teodor Streba C, Constantin Vere C, Rogoveanu I, editors. Hepatocellular Carcinoma - Advances in Diagnosis and Treatment. IntechOpen; 2018. [DOI: 10.5772/intechopen.76136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Zhu Y, Ortiz A, Costa M. Wrong place, wrong time: Runt-related transcription factor 2/SATB2 pathway in bone development and carcinogenesis. J Carcinog 2021;20:2. [PMID: 34211338 DOI: 10.4103/jcar.JCar_22_20] [Reference Citation Analysis]
3 Xu M, Xu X, Pan B, Chen X, Lin K, Zeng K, Liu X, Xu T, Sun L, Qin J, He B, Pan Y, Sun H, Wang S. LncRNA SATB2-AS1 inhibits tumor metastasis and affects the tumor immune cell microenvironment in colorectal cancer by regulating SATB2. Mol Cancer 2019;18:135. [PMID: 31492160 DOI: 10.1186/s12943-019-1063-6] [Cited by in Crossref: 58] [Cited by in F6Publishing: 69] [Article Influence: 19.3] [Reference Citation Analysis]
4 Cígerová V, Adamkov M, Drahošová S, Grendár M. Immunohistochemical expression and significance of SATB2 protein in colorectal cancer. Ann Diagn Pathol 2021;52:151731. [PMID: 33894556 DOI: 10.1016/j.anndiagpath.2021.151731] [Reference Citation Analysis]
5 Park CS, Nguyen LP, Yong D. Development of Colonic Organoids Containing Enteric Nerves or Blood Vessels from Human Embryonic Stem Cells. Cells 2020;9:E2209. [PMID: 33003541 DOI: 10.3390/cells9102209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Samad T, Wu SM. Single cell RNA sequencing approaches to cardiac development and congenital heart disease. Semin Cell Dev Biol 2021:S1084-9521(21)00096-3. [PMID: 34006454 DOI: 10.1016/j.semcdb.2021.04.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 De Michele S, Remotti HE, Del Portillo A, Lagana SM, Szabolcs M, Saqi A. SATB2 in Neoplasms of Lung, Pancreatobiliary, and Gastrointestinal Origins. Am J Clin Pathol 2021;155:124-32. [PMID: 32914850 DOI: 10.1093/ajcp/aqaa118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Sun Y, Mironova V, Chen Y, Lundh EPF, Zhang Q, Cai Y, Vasiliou V, Zhang Y, Garcia-Milian R, Khan SA, Johnson CH. Molecular Pathway Analysis Indicates a Distinct Metabolic Phenotype in Women With Right-Sided Colon Cancer. Transl Oncol 2020;13:42-56. [PMID: 31760268 DOI: 10.1016/j.tranon.2019.09.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
9 Roy SK, Shrivastava A, Srivastav S, Shankar S, Srivastava RK. SATB2 is a novel biomarker and therapeutic target for cancer. J Cell Mol Med 2020;24:11064-9. [PMID: 32885593 DOI: 10.1111/jcmm.15755] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Schmitt M, Silva M, Konukiewitz B, Lang C, Steiger K, Halfter K, Engel J, Jank P, Pfarr N, Wilhelm D, Foersch S, Denkert C, Tschurtschenthaler M, Weichert W, Jesinghaus M. Loss of SATB2 Occurs More Frequently Than CDX2 Loss in Colorectal Carcinoma and Identifies Particularly Aggressive Cancers in High-Risk Subgroups. Cancers 2021;13:6177. [DOI: 10.3390/cancers13246177] [Reference Citation Analysis]
11 Chen QY, Des Marais T, Costa M. Deregulation of SATB2 in carcinogenesis with emphasis on miRNA-mediated control. Carcinogenesis 2019;40:393-402. [PMID: 30916759 DOI: 10.1093/carcin/bgz020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
12 Kikuchi K, Fukunaga S, Ide F, Hoshino M, Inoue H, Miyazaki Y, Li TJ, Kusama K. Primary intestinal-type adenocarcinoma of the buccal mucosa: A case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol 2019;127:e61-70. [PMID: 29941401 DOI: 10.1016/j.oooo.2018.05.010] [Reference Citation Analysis]
13 Oh HH, Joo YE. Novel biomarkers for the diagnosis and prognosis of colorectal cancer. Intest Res 2020;18:168-83. [PMID: 31766836 DOI: 10.5217/ir.2019.00080] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
14 Lee W, Li X, Chandan VS. Hepatocellular carcinomas can be Special AT-rich sequence-binding protein 2 positive: an important diagnostic pitfall. Hum Pathol 2020;105:47-52. [PMID: 32946879 DOI: 10.1016/j.humpath.2020.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Dabir PD, Svanholm H, Christiansen JJ. SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary. APMIS 2018;126:494-500. [PMID: 29924451 DOI: 10.1111/apm.12854] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]